Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy. (December 2016)

• Record Type: Journal Article
• Authors: Bode, Axel; Rahbar, Kambiz; Konnert, Julia; Bögemann, Martin; Stegger, Lars
• Is Part Of: Clinical nuclear medicine. Volume 41:Number 12(2016)
• Publication Date: 2016-12
• Subjects: prostate cancer -- positron emission tomography -- PET/CT -- radium dichloride -- Xofigo; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000001374
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 66-year-old man with castration-resistant prostate carcinoma and multiple symptomatic bone mestastases was considered for 223 Ra-dichloride (Xofigo) therapy. Staging with 68 Ga-PSMA-PET/CT revealed additional extensive tumor involvement of the spine without relevant uptake in bone scintigraphy. Based on this imaging result, the patient was rescheduled for a PSMA-targeted therapy. Additional 68 Ga-PSMA-PET/CT may have a considerable benefit for patients considered for Xofigo.